Short answer
Progyny, Inc. (PGNY) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $329M (up 1.4% year over year) with net income of $24M.
Q1 2026 key financials · XBRL
- Revenue
- $329M
- +1.4% YoY
- Net income
- $24M
- +60.9% YoY
- Operating margin
- 10.8%
- Gross margin
- 25.3%
- EPS (diluted)
- $0.29
- +70.6% YoY
Source: XBRL data from the Progyny, Inc. (PGNY) Q1 2026 10-Q on SEC EDGAR. USD.
Progyny, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $328.5M, up 1% YoY from $324.0M; fertility benefits +$3.0M and Progyny Rx +$1.5M
- Gross margin 25.3% vs 23.4%; operating margin 10.8% vs 7.5%; net margin 7.4% vs 4.6%
- Best-performing line: fertility benefits revenue, up $3.0M; Progyny Rx revenue up $1.5M
- Net income $24.2M vs $15.1M; Adjusted EBITDA $56.6M vs $57.8M
- Client base 595 and members 7.179M, up from 555 and 6.689M at December 31, 2025
Risk Factors
- May 7, 2026 guidance exposed to revision from macroeconomic conditions, fertility medication shortages, and utilization trends
- Competitive pressure from healthcare consolidation and emerging fertility-focused PBMs threatening client retention and market share
- Tariffs on pharmaceutical drugs and components creating potential cost and supply disruptions for Progyny, customers, suppliers, and pharmacy partners
- Technology-sector concentration and largest-client dependence increasing exposure to workforce reductions and benefits-spending cuts
- Cybersecurity attacks on Progyny, provider clinics, specialty pharmacies, or vendors risking service disruption and confidential-data disclosure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Progyny, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.